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Background: Long-QT syndrome (LQTS) causes a prolongation of the QT-interval in the ECG leading to life threatening
tachyarrhythmia and ventricular fibrillation. One atypical form of LQTS, Timothy syndrome (TS), is associated with syndactyly,
immune deficiency, cognitive and neurological abnormalities as well as distinct cranio-facial abnormalities.
Case presentation: On a family with both children diagnosed with clinical LQTS, we performed whole exome sequencing
to comprehensively screen for causative mutations after a targeted candidate gene panel screen for Long-QT syndrome
target genes failed to identify any underlying genetic defect. Using exome sequencing, we identified in both affected
children, a p.402G > S mutation in exon 8 of the CACNA1C gene, a voltage-dependent Ca2+ channel. The mutation was
inherited from their father, a mosaic mutation carrier. Based on this molecular finding and further more careful clinical
examination, we refined the diagnosis to be Timothy syndrome (TS2) and thereby were able to present new therapeutic
approaches.
Conclusions: Our study highlights the difficulties in accurate diagnosis of patients with rare diseases, especially those with
atypical clinical manifestation. Such challenge could be addressed with the help of comprehensive and unbiased mutation
screening, such as exome sequencing.
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Long-QT syndrome [1,2] (LQTS) is a cardiac chanellopathy
characterized by QT prolongation and T-wave abnormalities
in the ECG causing syncope, life threatening arrhythmia
and sudden cardiac death due to torsade de pointes (TdP)
and ventricular fibrillation.
On a molecular level, most LQTS patients have mutations
in a set of ten genes (KCNQ1, KCNH2, SCN5A, KCNE1,
KCNE2, CAV3, SCN4B, AKAP9, SNTA1 and KCNJ5) with
~97% of all mutations within this gene panel falling into
the first three genes [3]. The remaining seven genes repre-
sent some rare cases of LQTS. However, in about 25%
of all studied families showing LQTS symptoms, no* Correspondence: Achim.Will@charite.de; Wei.Chen@mdc-berlin.de
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reproduction in any medium, provided the ormutations within the set of 10 candidate genes can be
found [3], indicating either a limitation in the testing
methods employed on the identified candidate genes or
the presence of additional genes related to LQTS.
A distinct form of LQTS is the syndactyly related TS
(also called LQT8) a rare autosome dominant disorder.
The first clinical cases were described as the ‘heart-hand
syndrome’ in the 1990’s [4-6] with a prolonged QT-interval
and syndactyly being present in 100% of described cases.
Additional cardinal features of TS include: bradycardia,
AV-Block, congenital heart disease, immune deficiency,
hypoglycemia, neurological and cognitive abnormalities
such as intellectual disability, autism and seizures as well
as distinctive cranio-facial abnormalities. Also, an associ-
ation of TS with hypertrophic cardiomyopathy has been
described [7].
In 2004, a missense mutation (p.406G >R) located in exon
8A of the gene CACNA1C, encoding the transmembraneLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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type calcium channel subunit alpha-1C), has been identified
to cause TS [8]. The mutation leads to almost complete loss
of voltage dependent channel-inactivation, thereby resulting
in intracellular calcium overload and subsequently delayed
repolarization of the respective cell. The vast majority of
described cases result from de-novo missense mutations.
Nevertheless, in one family with two affected children, mo-
saicism for the p.406G > R mutation was discovered in the
mother [8]. In 2005, Splawski et al. described two unrelated
individuals with severe prolongation of the QTc-interval
without syndactyly, in which two de novo mutations
(p.406G > R and p.402G > S) in Exon 8 of CACNA1C have
been identified to cause a related but distinct phenotype,
classified as Timothy syndrome 2 (TS2) [9]. In contrast to
the splice variant containing Exon 8A, Exon 8 is widely
expressed in heart and brain, consistent with the phenotype
of the described patients. Whereas patient one, described
by Splawski, presented with severe central nervous system
(CNS) and cardiac affection, patient two presented with se-
vere QTc prolongation but milder CNS affection which was
attributed to the somatic mosaicism for the mutation.
In this report, we describe a family with two affected
children initially diagnosed to have LQTS. After a candidateFigure 1 Pedigree and validation results for the causative CACNA1C G
symbols indicate the affected individuals. (b) Sanger sequencing traces val
well as the mosaic mutation in the father. (c) Restriction assay using enzym
mutation. A clear restriction pattern was found for both affected children, n
a mosaic restriction pattern was found for the father.gene panel test for LQTS failed to identify any causative
genetic defect, we referred to whole-exome sequencing and
identified a causative p.402G > S (exon 8) mutation in the
CACNA1C gene in both affected children. The mutation
was inherited from the father, who is mosaic for the specific
mutation. As a result, we refined the diagnosis to be
Timothy syndrome type 2 (TS2) although both patients
do not manifest the full clinical spectrum of classical
TS2. On one hand, our study highlights the difficulties in
accurate diagnosis of patients with rare diseases, especially
those with atypical clinical manifestation. On the other
hand, we demonstrated such challenge could be addressed
with the help of comprehensive and unbiased mutation
screening, such as exome sequencing.
Case presentation
Patients
The family is originated from Lebanon with two children
of non-consanguineous healthy parents (Figure 1a). Family
history is negative for cases of sudden cardiac death (SCD),
arrhythmia, LQTS or gross neurological abnormalities.
Electrocardiograms of both the father (who was found
to be a p.G402S mosaic variant carrier) and the mother
are unremarkable and show a normal QTc-interval. The402S mutation. (a) Pedigree of the Lebanese family. Blackened
idating the CACNA1C c.1204G > A mutation in both affected children as
e DdeI, specifically cleaving PCR amplicons carrying the c.1204G > A
o restriction pattern was found for the apparently healthy mother and
Fröhler et al. BMC Medical Genetics 2014, 15:48 Page 3 of 6
http://www.biomedcentral.com/1471-2350/15/48father’s 6 siblings who live in Lebanon were not investi-
gated (no ECGs). Both children present with significantly
prolonged QTc-intervals (Patient 1 468–547 ms, Patient 2
476–650 ms), T-wave alternans and recurring life threat-
ening arrhythmia since early childhood. After receiving
the molecular diagnosis, mild partial syndactyly of the
second/third toe, which usually is regarded as a normal
variant, was found in both patients as well as in their
father. It is speculative whether this finding could be re-
lated to the p.402G > S mutation, since the few reported
patients carrying this mutation do not show syndactyly
[9]. Both children do not meet the full clinical criteria
for classical TS apart from the prolonged QTc interval:
Their hearts are structurally and functionally normal,
they do not show any cranio-facial dysmorphies, they
do not suffer from recurrent infections and no other
major anomalies as manifested in TS (type 1) can be
detected (see Additional file 1).
The index patient is the 8 year old daughter (Patient
1) who presented VF/ TdP leading to cardiac arrest
and was successful resuscitated at the age of 2 months.
Antiarrhythmic therapy was started with beta blockers,
nicorandil and mexiletine, controlling TdP best with
high doses of propranolol and mexiletine. At the age of
4, her parents agreed to have an internal cardiac defibril-
lator (ICD) implanted, who delivered 2 adequate shock
since then. The patient developed generalized epilepsy
which is currently well controlled with levetiracetam.
Today, at eight years of age, the patient is unable to
speak and learned walking only at the age of seven. She
additionally shows evidence of a vast precocious puberty
which is not known to be associated with TS. The
neurological findings (epilepsy, developmental delay) are
rather attributed to hypoxic brain damage caused by
cardiac arrest and resuscitation than being part of TS.
Especially since the early neonatal development of the
patient has been entirely unremarkable. Moreover,
patient 2 unlike his sister reached the milestones of
psychomotor development at the expected times and
clinical workup failed to show any neurological abnor-
malities. He is the second child of the family and is now
six years old. He developed VF/ TdP at the age of 3 years
and was successfully resuscitated using his sister’s auto-
matic external defibrillator and received an ICD two
months later. As his sister, he was put on propranolol
and mexiletine. Since then, the patient has had frequent
episodes of VF and non-sustained ventricular tachycar-
dia and has received overall more than 40 adequate and
appropriate shocks. His antiarrhythmic therapy has been
modified several time, he was administered several
antiarrhythmic drugs (AAD): high-dose betablockers,
potassium-, magnesium- and calcium-antagonists as well
as Vaughn-Williams class Ia, Ib and Ic agents. None of
these AAD combinations shortened QTc-intervals orreduced VF episodes. Left- and right-cardiac sympathetic
denervation could also not reduce the arrhythmic episodes.
Today, quality of life of both patients is still significantly
affected by the continuing relapses of VF, especially in the
boy, who seems to be especially insusceptible to standard
therapeutic approaches.
Written informed consent was obtained from each family
member for the subsequent studies according to the
German Genetic Diagnostic Law (GenDG).
Candidate gene panel screening for LQTS
Given the diagnosis of LQTS for both children, LQTS
candidate gene panels I, II and III, including genes:
KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2 were
PCR amplified and Sanger-sequenced to identify muta-
tions. Neither this screen, nor a multiplex ligation probe
amplification (MLPA) of 40 regions of the target genes
identified any mutations or insertions/ deletions in the
regions screened (both analysis were performed at the
Center for Human Genetics and Laboratory Medicine,
Martinsried, Germany).
Exome sequencing and bioinformatics
All four family members were subjected to exome
sequencing. Genomic DNA was isolated from blood
samples using standard methods. Five micrograms of
genomic DNA were enriched using the Agilent Human
All Exon V4 kit (Agilent Technologies, Santa Clara,
CA, USA) following the manufacturer's protocol. A list
of screened genes and a list of assayed regions for these
probes is available on the Agilent website (https://earray.
chem.agilent.com/suredesign/).
Whole-exome libraries were sequenced on an Illumina
HiSeq 2000 system for 1x101 cycles following the manu-
facturer's instructions (Illumina, San Diego, CA, USA).
All raw sequencing reads were mapped onto UCSC hg19
[10] using BWA 0.5.9-r16 [11], mappings were con-
verted into BAM file format using samtools 0.1.18 [12].
Initial mappings were post-processed using GATK 1.3-
21 [13] following their ‘best practices V3’. In brief, reads
were realigned around sites of known insertions and
deletions (INDELs). Then, likely PCR duplicates were
detected using Picard 1.48 [12]. Finally, raw base quality
scores were empirically recalibrated. Single Nucleotide
Polymorphisms (SNPs) and short INDELs were identi-
fied using the UnifiedGenotyper from GATK and in
parallel using the variant caller included in samtools.
Variants were classified as novel or known variants de-
posited in dbSNP 135 [14]. Functional consequences of
each variant were annotated using snpEff 2.0.5d [15] for
UCSC hg19 RefSeq genes and ENSEMBL 65 human
gene models [10,16]. The potential deleterious effect was
evaluated using PolyPhen 2 [17], SIFT [18], PhyloP [19],
MutationTaster [20], GERP++ [21], LRT [22] and OMIM
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samtools were compared to increase both sensitivity and
specificity.
Mutation validation
To confirm the presence and identity of the p.402G > S
variant in CACNA1C exon 8, Sanger sequencing was
performed on PCR amplicons from genomic DNA cov-
ering that variant position. A restriction assay on the
same amplicons using the enzyme DdeI that specifically
cleaves amplicons carrying the mutation was also per-
formed to validate the mosaicism in the father.
Exome sequencing
All four family members were subjected to whole exome
sequencing. In total, we obtained 215 – 218 million single-
end 101 bp reads per sample, of which 98.5 – 98.7% could
be mapped onto the human genome. After removing
duplicated reads, which possibly derived from PCR arti-
facts, 48 – 50 million unique reads were mapped to the
targeted protein coding regions, resulting in an average of
96.9-101.2x coverage within the targeted coding region
(Table 1).
Using GATK and samtools, we detected 26,501 – 30,024
SNPs and INDELs in the exome of each family member,
of which 94.3 – 97.1% are known variants deposited in
dbSNP 135 (see Additional file 2). Given the pedigree, we
first searched for non-silent variants present in both
affected children but absent in both apparently healthy
parents. Whereas no such variants were found by GATK,
samtools outputs one such variant in exon 8 of the gene
CACNA1C (c.1204G >A, p.402G > S).
We then checked for the reason leading to the incon-
sistent results from samtools and GATK. While both
tools called the same genotypes in affected siblings as
well as their mother, the father was identified to carry
heterozygous or homozygous reference allele by GATK
(PHRED-scaled genotype quality 99) and samtools
(PHRED-scaled genotype quality 50), respectively. After
retrieving the original mapping data from the father, we
found 15 high-quality reads (9.9% of all 151 reads
aligned at this position) carrying the variant allele. ThisTable 1 Summary statistics for exome sequencing
All reads # mapped
reads
# uniquely
mapped reads
# non-redundan
uniquely mappe
reads
Father 215,270,552 212,495,384 207,507,067 88,105,506
Mother 218,495,007 215,280,440 210,261,330 84,480,091
Son 217,253,295 214,298,717 209,188,980 85,277,852
Daughter 218,048,872 214,904,784 209,988,667 89,229,385
Mean 217,266,932 214,244,831 209,236,511 86,773,209
sd 1,426,571 1,234,435 1,239,520 2,258,488relatively low non-reference allele frequency, indicating a
mosaic carrier, allowed GATK to call a heterozygous
genotype, whereas it does not pass the default samtools’
variant calling threshold.
Mutation validation
Sanger sequencing on the blood samples of all family
members not only confirmed the heterozygous p.402G >
S variant in both affected children but also the mosaic
genotype for this variant in the father (Figure 1b). The
father's mosaic genotype was also observed in his oral
mucosa swap sample at a similar allele frequency (see
Additional file 3). Both heterozygous and mosaic geno-
types could also be validated by a restriction assay using
DdeI, specifically cleaving amplicons containing the vari-
ant (Figure 1c).
Refined diagnosis and treatment
The p.G402S variant in exon 8 of the gene CACNA1C
has been previously associated with Timothy Syndrome
TS2 (MIM: 601005). In literature, treatment with multi-
potent ion-channel-blocker ranozaline in combination
with verapamil has been reported to be beneficial in a
patient with this distinct mutation [24]. This therapeuti-
cal approach is currently applied in our patients with
short follow up time.
Cell-culture-based experiments with Cav1.2. and
Timothy channels show that calcineurin inhibitors (e.g.
FK 506, cyclosporine A) stabilize the action potential of
the respective cells by increasing voltage dependent
channel-inactivation [25]. Theoretically this could be an-
other therapeutical approach in case of TS refractory to
conventional medical therapy.
Using whole-exome sequencing we identified a p.402G > S
mutation in exon 8 of the gene CACNA1C in a family with
two affected children, both presenting atypical form of
Timothy syndrome (TS2). This variant has been previously
described to alter the transmembrane segment S6 of do-
main I in the CACNA1C gene, thereby almost completely
disrupting voltage-dependence of this Ca2+-channel, leading
to a massively increased QT-interval in an electrocardio-
gram [9]. The CACNA1C isoform containing exon 8 ist
d
# non-redundant reads uniquely
mapped in targeted regions
Average sequencing
depth in target regions
49,357,904 100.29
47,828,952 97.15
47,758,981 96.87
49,872,405 101.19
48,704,561 98.88
1,072,618 2.19
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and brain, consistent with the phenotype of both patients.
A previous LQTS candidate gene panel screen returned
no diagnostic result since, at the time of evaluation, both
children only unequivocally manifest the LQTS part of the
Timothy Syndrome phenotype, together with an only
partial syndactyly that they even share with their father - a
feature quite easy to oversee by a cardiologist focusing on
their severe heart arrhythmia. Exome sequencing, as an
unbiased diagnostic aid however, clearly identified the
causative mutation after a careful analysis.
The p.402G > S mutation was inherited from the
mosaic father. However, a mosaic genotype, manifested
with a relatively low non-reference allele frequency in
the exome sequencing results is not susceptible to most
variant calling algorithms. Interestingly, although sam-
tools lead to the discovery of this mutation, a (somehow)
wrong genotype call was made by samtools, whereas the
correct genotype call of GATK resulted in filtering out
this variant from the list of autosome-dominant events,
given the father is not afflicted with Timothy syndrome.
Luckily, mosaicism is a rare event and most studies
will identify the same causative mutation using different
variant callers. However, care should be taken in case of
pedigrees with an atypical inheritance pattern where a
combination of variant callers with different genotyping
models/thresholds can provide a valuable list of discordant
genotype calls, thereby enriching for candidate mosaicisms.
Those variants might just be filtered out when relying
on a single variant caller.
Diagnosing patients with rare diseases is a complex mis-
sion that can easily take several years of clinical examina-
tions. Many different gene defects can give rise to clinically
indistinguishable phenotypes. Recent data show that up to
40% of all initial diagnosis are wrong [26,27]. Current
whole-exome/whole-genome sequencing technology, ap-
plied in clinical settings, can aid in correctly diagnosing
those patients, as demonstrated in this study. With the
ever decreasing sequencing costs, a global, truly unbiased
genomic screen, at a cost even below that of targeted gene
panel screens today, will be available in the clinic in
only a few years. Combined with a genotype-phenotype-
treatment resource, constantly expanding during such
kind of studies in the clinic, new therapeutic approaches
could be offered to the patient as an immediate benefit.
However, in such clinical context, controlled vocabular-
ies for phenotyping patients together with rigid data
protection strategies must be warranted at all times.
Additional legislative effort might be required for
recording, storing and accessing this kind of data. Fur-
thermore, a clear consent must be obtained regarding
how to proceed with incidental findings. Whether those
should be conveyed to the patient if requested, whether
to only convey results on ‘treatable diseases’ or evenonly to convey findings immediately relevant for the
disease studied must be agreed upon before initiating
such kind of studies. Finally, diagnosing a ‘syndrome’
might stigmatize the patient, so proper genetic counseling
by specialized physicians will be required for all such
molecular genetic diagnostics.
Conclusions
We have described a family with two affected children
initially diagnosed to have LQTS. After a candidate gene
panel screen for LQTS failed, we referred to whole-exome
sequencing of the whole family as a global, unbiased
method. As a result, we have identified a causative p.402G
> S mutation in the CACNA1C gene in both affected
children and showed that this mutation was inherited from
their mosaic father. Thereby, we could refine the diagnosis
for both children to be Timothy Syndrome (TS2), a very
rare atypical form of LQTS. This refined diagnosis immedi-
ately opened new therapeutic options for the patient. Our
study strongly supports the benefit of exome sequencing in
clinical diagnosis of complex cases and soon might become
a widely used tool in clinical settings.
Additional files
Additional file 1: Table S1. Clinical features of Timothy Syndrome in
the patients. Phenotypic features of Timothy Syndrome (TS1, TS2), as well
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